Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Diversification is crucial for investment success. It helps mitigate risks and can lead to better returns in the long run.
27,279 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
May 2026 brings a packed streaming slate as platforms roll out new originals and surprises, shaping market chatter ar...
A celebrity legal shock isn’t just a headline—it can ripple through finances. This article breaks down practical step...
A high-income professional taps a tax-smart 401(k) path—after-tax contributions plus in-plan Roth conversions—to turn...
Trump heads Beijing high-stakes summit as markets watch for any change in US-China policy on crypto, potentially resh...
A new privacy framework lets bitcoin holders hide more balances and transfers by moving BTC to a shielded ERC-20 on S...
Singapore Airlines defends its decision to invest in Air India as it reports record revenue but a steep profit drop d...
As CME Group and ICE push 24/7 crypto trading, a heated clash with an offshore venue shines a spotlight on who contro...
Goldman Sachs exited all XRP and SOL ETF positions in Q1 2026, according to the latest 13F filing. The move shifts th...
Astera Labs’ stock jumped after management laid out a firm timetable for a new switch and signaled growing opportunit...
New York moves toward banning potassium bromate in flour, potentially altering crusts and prices for thousands of piz...
A renewed bond market selloff is sharpening focus on fiscal risks. Analysts say the u.s. debt ‘elephant room’ could q...